Table 2. Summary statistics for overall survival under various glioma grades and gene selections.
| Median overall survival months: with aberration | Median overall survival months: with no aberration | Total number of patients with aberration | Total number of patients without aberration | p value | |
|---|---|---|---|---|---|
| LGG/61 genes Grade 2 and 3 | 65.70 | 94.45 | 46 | 11 | 0.035 |
| LGG/61 genes Grade 2 | 67.41 | 79.93 | 25 | 5 | 0.265 |
| LGG/61 genes Grade 3 | 48.98 | 94.45 | 21 | 6 | 0.056 |
| LGG/16 genes Grade 2 and 3 | 62.91 | 94.45 | 33 | 24 | 0.002 |
| LGG/16 genes Grade 2 | 63.50 | 79.93 | 20 | 10 | 0.054 |
| LGG/16 genes Grade 3 | 62.91 | 94.45 | 13 | 14 | 0.030 |
| LGG/8 genes Grades 2 and3 | 25.89 | 79.93 | 23 | 34 | <10−5 |
| LGG/8 genes Grade 2 | 25.89 | 78.15 | 14 | 16 | <10−3 |
| LGG/8 genesGrade 3 | 43.86 | 87.39 | 9 | 18 | 0.025 |
| GBM/61 genes | 13.3 | 14.03 | 95 | 9 | 0.991 |
| GBM/16 genes | 12.94 | 14.03 | 62 | 42 | 0.430 |
| GBM/8 genes | 16.59 | 12.55 | 34 | 70 | 0.011 |
Median overall survival times, total numbers, and p values from the 61, 16, and 8 gene selections for both LGG (with further differentiation by grade) and GBM. While only weak evidence exists for differences of median overall survival times under the 61 gene set for Grade 2 patients, both the 16 gene set and 8 gene set produce statistically strong evidence for distinct subpopulations.